Mass General Brigham Ventures
399 Revolution Drive, Suite 999, Somerville, MA, 02145, United States
Overview
Venture capital firm investing in early-stage healthcare innovations.
Founded
2008
Deals ยท 12mo
5
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Abcuro | Aug 2026Participated | $66 MSeries D | |
Claris Biotherapeutics | Jul 2026Participated | $118 MSeries B | |
InStride Health | Jun 2026Participated | $30 MSeries C | |
Violet Therapeutics | May 2026Participated | $5 MSeed | |
Nocion Therapeutics | Jan 2026Participated | $23 MSeries B | |
Affinia Therapeutics | Oct 2025Participated | $40 MSeries C | |
Predicta Biosciences | Oct 2025Participated | $23 MSeries A | |
Carta Healthcare | May 2025Participated | $18 MSeries B | |
Abcuro | Feb 2025Participated | $200 MSeries C | |
Rippl | Oct 2024Participated | $23 MSeries A | |
Rippl | Oct 2024Participated | $23 MSeries A | |
Tuesday Health | May 2024Participated | $60 MOther Equity | |
Abcuro | Aug 2026Participated | $66 MSeries D | |
Claris Biotherapeutics | Jul 2026Participated | $118 MSeries B | |
InStride Health | Jun 2026Participated | $30 MSeries C | |
Violet Therapeutics | May 2026Participated | $5 MSeed | |
Nocion Therapeutics | Jan 2026Participated | $23 MSeries B | |
Affinia Therapeutics | Oct 2025Participated | $40 MSeries C | |
Predicta Biosciences | Oct 2025Participated | $23 MSeries A | |
Carta Healthcare | May 2025Participated | $18 MSeries B | |
Abcuro | Feb 2025Participated | $200 MSeries C | |
Rippl | Oct 2024Participated | $23 MSeries A | |
Rippl | Oct 2024Participated | $23 MSeries A | |
Tuesday Health | May 2024Participated | $60 MOther Equity |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 0 | 3 |
| Series A | 2 | 6 |
| Series B | 1 | 11 |
| Series C+ | 0 | 6 |
| Other Equity | 0 | 1 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Jan '21 | 1 |
| Feb '21 | 0 |
| Mar '21 | 0 |
| Apr '21 | 0 |
| May '21 | 1 |
| Jun '21 | 1 |
| Jul '21 | 0 |
| Aug '21 | 1 |
| Sep '21 | 3 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 1 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 2 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 1 |
| Feb '23 | 1 |
| Mar '23 | 1 |
| Apr '23 | 0 |
| May '23 | 1 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 1 |
| Sep '23 | 1 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 2 |
| Apr '24 | 0 |
| May '24 | 1 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 2 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 1 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 1 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 2 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 1 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 1 |
| Jun '26 | 1 |
| Jul '26 | 1 |
| Aug '26 | 1 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 28 |
| Networks, Cloud & Communication | 3 |
| Professional Services | 3 |
| AI & Machine Learning | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 1 |
| $5M-$10M | 0 |
| $10M-$25M | 7 |
| $25M-$50M | 5 |
| $50M-$100M | 12 |
| $100M-$250M | 5 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 3 of 3 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 26 |
| Europe | 2 |
| India | 2 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| F-Prime Capital | 7 |
| Google Ventures | 7 |
| Pontifax | 6 |
| Sanofi Ventures | 6 |
| Alexandria Venture Investments | 5 |
| General Catalyst | 5 |
| RA Capital Management | 5 |
| Samsara BioCapital | 5 |
| ARCH Venture Partners | 4 |
| Casdin Capital | 4 |
| New Enterprise Associates | 4 |
| OrbiMed | 4 |
| Sectoral Asset Management | 4 |
| Aisling Capital | 3 |
| Arkin Bio Ventures | 3 |
| Bain Capital Life Sciences | 3 |
| Eli Lilly and Company | 3 |
| Eurofarma Ventures | 3 |
| Mission BioCapital | 3 |
| Novo Holdings | 3 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 3 | 10% |
| Participating | 27 | 90% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 0 | 0% |
| Co-led | 3 | 100% |
Team
Partner